
GOSS Earnings
Gossamer Bio Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Gossamer Bio Inc(GOSS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Gossamer Bio Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-11 | After Hours | -0.18 | - | - | 4.49M | - | - | - | - |
FY2025Q1 | 2025-05-15 | After Hours | -0.19 | -0.16 | +15.79 | 3.95M | 9.89M | +150.53 | -0.95 | +9.52 |
FY2024Q3 | 2024-11-07 | - | -0.18 | -0.14 | +22.22 | 7.60M | 9.48M | +24.73 | - | -8.00 |
FY2024Q1 | 2024-05-07 | - | -0.19 | -0.19 | - | - | - | - | -6.27 | -7.81 |
FY2023Q4 | 2024-03-05 | - | -0.20 | -0.21 | -5.00 | - | - | - | - | -7.59 |
FY2023Q3 | 2023-11-09 | - | -0.20 | -0.21 | -5.00 | - | - | - | -7.56 | +36.30 |
FY2023Q2 | 2023-08-08 | - | -0.49 | -0.45 | +8.16 | - | - | - | -5.43 | -9.30 |
- | 2023-05-09 | - | -0.55 | -0.52 | +5.45 | - | - | - | - | -12.50 |
- | 2023-03-17 | - | -0.62 | -0.59 | +4.84 | - | - | - | -8.48 | +1.90 |
- | 2022-11-03 | - | -0.66 | -0.65 | +1.52 | - | - | - | - | -6.13 |
GOSS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Gossamer Bio Inc reported performance for FY2025Q2, announced on 2025-08-11. The company achieved an EPS of , compared to analyst estimates of -0.18 by % . Revenue for the quarter reached 0.00 compared to expectations of 4.49M by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Gossamer Bio Inc growth trajectory and strategic initiatives.
GOSS Earnings Forecast
Looking ahead, Gossamer Bio Inc(GOSS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 28.55%, while EPS estimates have been Revise Upward by 11.16%. For the upcoming , revenue estimates have been adjusted Go Up by 103.92% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Gossamer Bio Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between GOSS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+28.55%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward

+11.16%
In Past 3 Month
Stock Price
Go Up

+103.92%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:26.71M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price2.08
GOSS Revenue and EPS Performance: A Historical Perspective
Gossamer Bio Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-11,After Hours):
EPS: (Actual) vs.-0.18 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 4.49M (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
FY2025Q1 (2025-05-15,After Hours):
EPS: -0.16 (Actual) vs.-0.19 (Estimate) (15.79%)
Revenue: 9.89M (Actual) vs. 3.95M (Estimate) (150.53%)
Price Reaction: -0.95%(1-Day), 9.52%(5-Day)
FY2024Q3 (2024-11-07,):
EPS: -0.14 (Actual) vs.-0.18 (Estimate) (22.22%)
Revenue: 9.48M (Actual) vs. 7.60M (Estimate) (24.73%)
Price Reaction: 0.00%(1-Day), -8.00%(5-Day)
Earnings Reaction
The chart below shows how GOSS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GOSS sees a +8.69% change in stock price 10 days leading up to the earnings, and a +1.44% change 10 days following the report. On the earnings day itself, the stock moves by -2.64%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -0.95% on the day following the earnings release and then changed by 5.71% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Summary
Neutral
2025-05-17
The earnings call presented mixed signals: EPS beat expectations, but guidance remains negative. Regulatory challenges and competitive pressures pose risks. The Q&A highlighted demand for trials but also revealed management's evasiveness on critical details, which might concern investors. Although EPS improved, the lack of clear shareholder return strategy and ongoing challenges suggest a neutral stock movement.
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Summary
Neutral
2025-05-15
The earnings call reveals mixed signals. Financial performance shows some improvement, with increased revenue and reduced net loss. However, high R&D expenses and the critical dependency on clinical trial outcomes pose risks. The Q&A session highlights management's confidence in trial safety and market potential but also reveals uncertainties in patient enrollment and regulatory milestones. Overall, the sentiment is balanced with positive and negative elements, resulting in a neutral rating for the stock's short-term movement.
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Summary
Neutral
2025-05-15
The earnings call showed improved net loss figures and cost management, but the Q&A revealed some uncertainties, particularly around enrollment and regulatory milestones. While management expressed confidence in their safety profile and global trial expansion, they avoided direct answers on key metrics, raising concerns. The lack of clear guidance and the decision to push data into 2026 may temper investor enthusiasm, resulting in a neutral stock price reaction.
People Also Watch

SERA
Sera Prognostics Inc
2.870
USD
-1.03%

BLRX
BioLine RX Ltd
4.010
USD
-2.91%

ESOA
Energy Services Of America Corp
10.900
USD
-1.89%

SKIN
Beauty Health Co
1.600
USD
-5.33%

GASS
StealthGas Inc
6.800
USD
-2.30%

FINW
Finwise Bancorp
17.900
USD
+2.40%

SMID
Smith-Midland Corp
35.240
USD
-5.50%

ODV
Osisko Development Corp
2.190
USD
-2.67%

HSHP
Himalaya Shipping Ltd
6.780
USD
-0.73%

UHG
United Homes Group Inc
3.750
USD
-11.76%
FAQ

What were the key highlights of GOSS’s latest earnings report for FY2025Q2?
GOSS reported its FY2025Q2 earnings on 2025-08-11, showcasing a revenue of 0.00 against an estimate of 4.49M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.18 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did GOSS’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for GOSS for undefined?

How does GOSS’s stock price correlate with earnings forecast revisions?

What should investors expect from GOSS’s next earnings report?
